GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Net Interest Income

Actelion (Actelion) Net Interest Income : $6 Mil (TTM As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Actelion's net interest income for the three months ended in Mar. 2017 was $1 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2017 was $6 Mil.

Actelion Net Interest Income Historical Data

The historical data trend for Actelion's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Net Interest Income Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -68.38 -59.03 -34.02 -20.26 3.65

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.23 3.91 1.29 -0.11 1.02

Actelion Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actelion Net Interest Income Related Terms

Thank you for viewing the detailed overview of Actelion's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (Actelion) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Net Interest Income
Comparable Companies
ALXN XKRX:207940 SGEN REGN INCY XKRX:068270 HKSE:01177 XBRU:UCB OCSE:GMAB HKSE:02269 BMRN HKSE:06160 XAMS:GLPG ALNY ARRY NBIX SZSE:300122 IONS JAZZ TECH
Traded in Other Exchanges
N/A
Address
Website
http://www.actelion.com
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson • 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 01-24-2017

Actelion Still On Growth Track

By reports.droy reports.droy • 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 02-14-2017